These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25860376)

  • 1. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.
    Sidharta PN; Treiber A; Dingemanse J
    Clin Pharmacokinet; 2015 May; 54(5):457-71. PubMed ID: 25860376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macitentan: first global approval.
    Patel T; McKeage K
    Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
    Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
    Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan for the treatment of pulmonary arterial hypertension.
    Sood N
    Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects.
    Sidharta PN; Dietrich H; Dingemanse J
    Clin Drug Investig; 2014 Aug; 34(8):545-52. PubMed ID: 24861134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
    Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
    Dhillon S
    Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
    Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of a novel dual endothelin receptor antagonist, macitentan (Opsumit
    Takahashi S; Horie R; Yokoyama Y
    Nihon Yakurigaku Zasshi; 2017; 149(1):49-58. PubMed ID: 28049880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.